DCRM SCIENCESDCRM SCIENCESWe're building a new European pharmaceutical company. Many medicines with strong clinical evidence never reach European patients — because they were developed for other markets, discontinued for financial or strategic reasons, or simply lost their path to market. We find them, acquire the rights, and bring them to Europe.
Wherever a medicine was developed, and whatever paused its path to market, we look for the same three things.
A patient population with limited or no effective treatment available today.
A real improvement over the current standard of care — not a marginal difference.
Safety and efficacy data robust enough to support a European market-entry pathway.
We believe Europe has the scientific talent, healthcare systems and regulatory environment to be home to globally relevant pharmaceutical companies — and we're building one, one medicine at a time. If you hold the rights to an asset that fits this profile, reach out and we can usually tell within days whether it's a fit.